Our Services
Medical Information
Helpful Resources
Published on: 9/23/2026
Adults ages 75 and older are recommended to receive a single dose of the RSV vaccine, along with adults ages 50 to 74 who have conditions that raise their risk of severe illness, such as chronic heart or lung disease, diabetes, kidney or liver disease, weakened immune systems, obesity, or who live in a nursing home. Pregnant people may instead be offered the maternal RSV vaccine between 32 and 36 weeks of pregnancy during RSV season to protect the newborn. Timing, prior RSV vaccination, and individual risk factors all affect whether you need a dose now, so there are several important details to consider below before deciding.
If you are unsure whether your symptoms point to RSV, flu, COVID-19, or something else, a free, instant, online symptom check can help you make sense of what you are feeling in just a few minutes. It asks targeted questions about your symptoms, age, and health history, then suggests possible causes and the right level of care, so you can walk into your next appointment informed and prepared rather than guessing.
Last reviewed for medical accuracy: 09/23/2026
Respiratory syncytial virus (RSV) is a common cause of seasonal respiratory illness. While many people think of RSV as a childhood infection, it can also lead to serious illness in adults—particularly older adults and those with certain health conditions. An effective RSV vaccine for adults is now available, offering protection against severe disease, hospitalization, and complications.
Most adults recover from RSV with rest and supportive care. However, RSV can cause:
In older adults and people with chronic health issues, RSV may lead to hospital stays, prolonged recovery, or serious complications. Vaccination reduces the risk of severe illness and eases pressure on hospitals and health care systems.
Current health guidelines recommend RSV vaccination for:
Adults aged 60 years and older
Adults 19–59 years old with certain health conditions
Other factors to consider
If you fall into any of these categories, talk to your health care provider about whether you should receive the RSV vaccine for adults.
Like other adult vaccines, the RSV shot is generally safe and well tolerated. Common side effects include:
These symptoms usually resolve within a day or two. Serious side effects are rare. If you experience shortness of breath, chest pain, or an allergic reaction (hives, swelling of the face or throat), seek medical attention immediately.
Check with your insurance provider; RSV vaccination is often covered under adult immunization plans. If you’re unsure about costs or coverage, call your insurer or pharmacy.
If you experience respiratory symptoms—such as cough, fever, or difficulty breathing—you don’t have to wait in uncertainty. Consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. It can help you decide whether you need to rest at home, see a health care provider, or seek immediate care.
Vaccination decisions should always be personalized. Discuss these points with your doctor:
Be open about any previous vaccine reactions or allergy history. Your doctor can help you weigh benefits versus potential risks and develop a plan that suits your health needs.
“I’m healthy—do I really need an RSV vaccine?”
Even healthy adults over 60 can experience complications from RSV. Vaccination lowers your risk of severe illness and helps protect those around you, including infants and older family members.
“Can I get RSV from the vaccine?”
No. The vaccine does not contain live virus and cannot cause RSV infection.
“Will it interfere with my other vaccines?”
RSV vaccines can be given alongside other adult vaccines, but always check with your provider to coordinate timing.
The development of an RSV vaccine for adults marks a major step in preventing serious respiratory illness across the lifespan. If you are 60 or older, or if you have chronic health conditions between ages 19 and 59, now is the time to talk with your health care provider about RSV vaccination. Protection starts before the RSV season, so schedule your vaccine appointment as early as possible.
Remember:
If you experience any concerning symptoms or need guidance on your next steps, try a free, online symptom check, using the doctor approved Ubie Symptom Checker. And above all, speak to a doctor about anything that could be life threatening or serious. Your health is worth every moment of attention.
(References)
* Mazur NI, Terstappen J, Baral R, Bardají A, Beutels P, Buchholz UJ, Cohen C, Crowe JE Jr, Cutland CL, Eckert L, Feikin D, Fitzpatrick T, Fong Y, Graham BS, Heikkinen T, Higgins D, Hirve S, Klugman KP, Kragten-Tabatabaie L, Lemey P, Libster R, Löwensteyn Y, Mejias A, Munoz FM, Munywoki PK, Mwananyanda L, Nair H, Nunes MC, Ramilo O, Richmond P, Ruckwardt TJ, Sande C, Srikantiah P, Thacker N, Waldstein KA, Weinberger D, Wildenbeest J, Wiseman D, Zar HJ, Zambon M, Bont L. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. Lancet Infect Dis. 2023 Jan;23(1):e2-e21. doi: 10.1016/S1473-3099(22)00291-2. Epub 2022 Aug 8. PMID: 35952703; PMCID: PMC9896921.
* Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Campora L, Dezutter N, de Schrevel N, Fissette L, David MP, Van der Wielen M, Kostanyan L, Hulstrøm V, AReSVi-006 Study Group. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. N Engl J Med. 2023 Feb 16;388(7):595-608. doi: 10.1056/NEJMoa2209604. PMID: 36791160.
* Agac A, Kolbe SM, Ludlow M, Osterhaus ADME, Meineke R, Rimmelzwaan GF. Host Responses to Respiratory Syncytial Virus Infection. Viruses. 2023 Sep 26;15(10). doi: 10.3390/v15101999. Epub 2023 Sep 26. PMID: 37896776; PMCID: PMC10611157.
* Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Verheust C, Dezutter N, Gruselle O, Fissette L, David MP, Kostanyan L, Hulstrøm V, Olivier A, Van der Wielen M, Descamps D, AReSVi-006 Study Group. Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons. Clin Infect Dis. 2024 Jun 14;78(6):1732-1744. doi: 10.1093/cid/ciae010. PMID: 38253338; PMCID: PMC11175669.
* Wildenbeest JG, Lowe DM, Standing JF, Butler CC. Respiratory syncytial virus infections in adults: a narrative review. Lancet Respir Med. 2024 Oct;12(10):822-836. doi: 10.1016/S2213-2600(24)00255-8. Epub 2024 Sep 9. PMID: 39265602.
* Terstappen J, Hak SF, Bhan A, Bogaert D, Bont LJ, Buchholz UJ, Clark AD, Cohen C, Dagan R, Feikin DR, Graham BS, Gupta A, Haldar P, Jalang'o R, Karron RA, Kragten L, Li Y, Löwensteyn YN, Munywoki PK, Njogu R, Osterhaus A, Pollard AJ, Nazario LR, Sande C, Satav AR, Srikantiah P, Stein RT, Thacker N, Thomas R, Bayona MT, Mazur NI. The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access. Lancet Infect Dis. 2024 Dec;24(12):e747-e761. doi: 10.1016/S1473-3099(24)00455-9. Epub 2024 Sep 23. PMID: 39326422; PMCID: PMC12311909.
* Payne AB, Watts JA, Mitchell PK, Dascomb K, Irving SA, Klein NP, Grannis SJ, Ong TC, Ball SW, DeSilva MB, Natarajan K, Sheffield T, Bride D, Arndorfer J, Naleway AL, Koppolu P, Fireman B, Zerbo O, Timbol J, Goddard K, Dixon BE, Fadel WF, Rogerson C, Allen KS, Rao S, Mayer D, Barron M, Reese SE, Rowley EAK, Najdowski M, Ciesla AA, Mak J, Reeves EL, Akinsete OO, McEvoy CE, Essien IJ, Tenforde MW, Fleming-Dutra KE, Link-Gelles R. Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis. Lancet. 2024 Oct 19;404(10462):1547-1559. doi: 10.1016/S0140-6736(24)01738-0. PMID: 39426837; PMCID: PMC13286031.
* Cilloniz C, Torres A. Respiratory syncytial virus infections in adults. Med Clin (Barc). 2025 Apr 11;164(7):361-368. doi: 10.1016/j.medcli.2024.11.024. Epub 2025 Feb 5. PMID: 39915191.
* Scott J, Abers MS, Marwah HK, McCann NC, Meyerowitz EA, Richterman A, Fleming DF, Holmes EJ, Moat LE, Redepenning SG, Smith EA, Stoddart CJ, Sundaram ME, Ulrich AK, Alba C, Anderson CJ, Arpey MK, Borre E, Ladines-Lim J, Mehr AJ, Rich K, Watts C, Basta NE, Jarolimova J, Walensky RP, Dugdale CM. Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025-2026. N Engl J Med. 2025 Dec 4;393(22):2221-2242. doi: 10.1056/NEJMsa2514268. Epub 2025 Oct 29. PMID: 41160817.
* Jabagi MJ, Bertrand M, Gabet A, Kolla E, Olié V, Zureik M. Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus-Related Hospitalization in Newborns. JAMA. 2026 Mar 3;335(9):787-798. doi: 10.1001/jama.2025.24082. PMID: 41428474; PMCID: PMC12723599.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.